Current US FDA-approved triplet regimens for management of RRMM in the second line
| Regimen (study) . | Survival outcomes, PFS (mo) and OS (mo) . | Median lines of therapy (range) . | Included anti-CD38 mAb–exposed/ refractory patients . | Included Len-refractory patients . |
|---|---|---|---|---|
| DPd (APOLLO) | Median OS 34.4 (95% CI, 23.7-40.3) DPd vs 23.7 (95% CI, 19.6-29.4) Pd | 2 (1-5) | No | Yes |
| KRd (ASPIRE) | Median PFS 26.1 (95% CI, 23.3-30.5) KRd vs 16.6 (95% CI, 15-20.6; P < .001) Rd Median OS 48.3 (95% CI, 42.4-52.8) KRd vs 40.4 (95% CI, 33.6-44.4; P = .0045) Rd | 2 (1-3) | No | No |
| SVd (BOSTON) | Median PFS 13.9 SVd vs 9.46 Vd (P = .0075) | 2 (1-3) | Yes | Yes |
| DKd (CANDOR) | Median PFS 28.4 DKd vs 15.2 Kd | 2 (1-5) | No | Yes |
| DVd (CASTOR) | Median PFS 16.7 DVd vs 7.1 Vd (P < .0001) | 2 (1-9) | No | Yes |
| EloRd (ELOQUENT-2) | Median PFS 19.4 EloRd vs 14.9 Rd (P = .014) Median OS 43.7 EloRd vs 39.6 Rd (P = 0.025) | 2 (1-4) | No | No |
| IsaKd (IKEMA) | Median PFS 35.7 (95% CI, 25.8-44.0) IsaKd vs 19.2 (95% CI, 15.8-25.0) Kd | 2 (1-4) | No | Yes |
| PVd (OPTIMISMM) | Median PFS 11.2 (95% CI, 9.66-13.73) PVd vs 7.1 (95% CI, 5.88-8.48; P < .0001) Vd | 2 (1-2) | No | Yes |
| DRd (POLLUX) | Median PFS 44.5 (95% CI, 34.1-NE) DRd vs 17.5 (95% CI, 13.9-20.8; P < .0001) Rd 65% vs 57% OS | 1 (1-11) | No | Yes |
| IxaRd (TOURMALINE-MM1) | Median PFS 19.4 IxaRd vs 14.9 Rd (P = 0.0014) Median OS 43.7 IxaRd vs 39.6 Rd (P = 0.025) | Range: 1-3 | No | No |
| Regimen (study) . | Survival outcomes, PFS (mo) and OS (mo) . | Median lines of therapy (range) . | Included anti-CD38 mAb–exposed/ refractory patients . | Included Len-refractory patients . |
|---|---|---|---|---|
| DPd (APOLLO) | Median OS 34.4 (95% CI, 23.7-40.3) DPd vs 23.7 (95% CI, 19.6-29.4) Pd | 2 (1-5) | No | Yes |
| KRd (ASPIRE) | Median PFS 26.1 (95% CI, 23.3-30.5) KRd vs 16.6 (95% CI, 15-20.6; P < .001) Rd Median OS 48.3 (95% CI, 42.4-52.8) KRd vs 40.4 (95% CI, 33.6-44.4; P = .0045) Rd | 2 (1-3) | No | No |
| SVd (BOSTON) | Median PFS 13.9 SVd vs 9.46 Vd (P = .0075) | 2 (1-3) | Yes | Yes |
| DKd (CANDOR) | Median PFS 28.4 DKd vs 15.2 Kd | 2 (1-5) | No | Yes |
| DVd (CASTOR) | Median PFS 16.7 DVd vs 7.1 Vd (P < .0001) | 2 (1-9) | No | Yes |
| EloRd (ELOQUENT-2) | Median PFS 19.4 EloRd vs 14.9 Rd (P = .014) Median OS 43.7 EloRd vs 39.6 Rd (P = 0.025) | 2 (1-4) | No | No |
| IsaKd (IKEMA) | Median PFS 35.7 (95% CI, 25.8-44.0) IsaKd vs 19.2 (95% CI, 15.8-25.0) Kd | 2 (1-4) | No | Yes |
| PVd (OPTIMISMM) | Median PFS 11.2 (95% CI, 9.66-13.73) PVd vs 7.1 (95% CI, 5.88-8.48; P < .0001) Vd | 2 (1-2) | No | Yes |
| DRd (POLLUX) | Median PFS 44.5 (95% CI, 34.1-NE) DRd vs 17.5 (95% CI, 13.9-20.8; P < .0001) Rd 65% vs 57% OS | 1 (1-11) | No | Yes |
| IxaRd (TOURMALINE-MM1) | Median PFS 19.4 IxaRd vs 14.9 Rd (P = 0.0014) Median OS 43.7 IxaRd vs 39.6 Rd (P = 0.025) | Range: 1-3 | No | No |
Doublet FDA-approved options are not included in this table. KCyD (MYX.1/MCRN-00) and KPd (EMN011/H0114) are not included although they are strongly supported by smaller phase 2 studies.
NE, not evaluable.